Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 180

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 180
---
 particular for clinical trials in preparation for marketing approval and in preparation for commercialization; |

| • |     | the costs of any third-party products used in Kineta’s combination clinical trials that are not covered by such third party or other sources; |

| • |     | the costs associated with hiring additional personnel and consultants as Kineta’s preclinical, manufacturing and clinical activities increase; |

| • |     | the receipt of marketing approval and revenue received from any commercial sales of any of Kineta’s product candidates, if approved; |

| • |     | the cost of commercialization activities for any of Kineta’s product candidates, if approved, including marketing, sales and distribution costs; |

| • |     | the emergence of competing therapies and other adverse market developments; |

| • |     | the ability to establish and maintain strategic collaboration, licensing or other arrangements and the financial terms of such agreements; |

| • |     | the extent to which Kineta in-licenses or acquires other products and technologies; |

| • |     | the amount and timing of any payments Kineta may be required to make pursuant to its current or future license agreements; |

| • |     | the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; |

104

| • |     | Kineta’s need and ability to retain key management and hire scientific, technical and business personnel; |

| • |     | Kineta’s implementation of additional internal systems and infrastructure, including operational, financial and management information systems; |

| • |     | Kineta’s costs associated with expanding its facilities or building out its laboratory space; |

| • |     | the effects of the disruptions to and volatility in the credit and financial markets in the United States and worldwide from the conflict between Russia and Ukraine and the conflict in Israel and the Gaza Strip; and |

| • |     | the costs of operating as a public company. |

**Kineta will require additional capital to achieve its business objectives. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable Kineta to continue to implement its long-term business strategy. Further, Kineta’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from inflation, changes in interest rates, geopolitical instability